Last Updated on October 19, 2024 by The Health Master
New Delhi: The Indian Government has decided to hasten the approvals for mega bulk drugs parks in the country to counter the China’s dominance in the sector.
Bulk drugs, also known as active pharmaceutical ingredients (API), are the raw materials for the manufacture of drugs. For example, paracetamol is the API for Crocin.
At present, Indian drug makers import around 70 per cent of their total bulk drugs requirement from China. The government had informed the Lok Sabha that the country’s drug makers imported bulk drugs and intermediates worth $2.4 billion from China in the 2018-19 fiscal.
To fight this dependence, the central government has now cleared four proposals to set up bulk drug parks, ThePrint has learnt. The Department of Pharmaceuticals (DoP), under the Ministry of Chemicals and Fertilisers, has given ‘in-principle approvals’ to the projects in Himachal Pradesh, Telangana, Andhra Pradesh and Assam.
“The final approval will be given as soon as they show us the required documentation and within two years of final approval, the projects should be operational,” a senior official from the ministry told ThePrint.
More perks in new plan
Under its new plan, the government is promising to also fund these projects by providing up to Rs 100 crore for each of the projects along with other facilities such as effluent treatment plants, power plants, incubation facilities, common logistic facilities and an advance common testing centre.
“We will give 70 per cent of the total cost of the project, or upto Rs 100 crore, whichever is less,” the official quoted above said. “Those whose proposals have been accepted will now have to show us the required permissions along with funding documents for the rest of the money.”
“We will also provide special purpose vehicles (SPVs) to build the necessary infrastructure and get the clearances for these parks, so that manufacturers can easily start their trade,” the official explained.
Last project a non-starter
The efforts to counter the Chinese began in 2013 when the then Congress-led UPA government set up a high-level committee under Dr V.M. Katoch, former secretary, Department of Health Research.
The objective of the committee was to carefully study the whole issue of bulk drugs, their importance, and the Indian drug market’s dependence on China. The committee outlined a package of interventions and concessions required to reduce the dependence on China. Based on the report, the idea of setting up bulk drug parks was proposed.
The prices of Chinese bulk drugs also began increasing putting further pressure on the input costs of Indian drug makers.
